Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation

- ERL-SBE-β-CD was prepared for ERL oral bioavailability enhancement.
- Stoichiometric ratio 1:1.05 molar ratio was confirmed by Job's plot.
- Quality by design approach was adopted in ERL-SBE-β-CD development.
- Molecular level interactions in ERL-SBE-β-CD were studied by in silico computation.
- Inclusion complex phenomenon was proved by 1H NMR and ROESY NMR studies.